Available data is not usable data. Why the application layer decides whether a data project pays off – and who is allowed to build a view.
The data flows, the project is signed off – and production still uses Excel. Why this gap appears systematically, and where the project boundary sits.
What can the framework do that Inmation cannot? Why the question matters – and which question actually decides it in operations.
When does technology alone stop being enough for a data project in pharma? When systems, context, and adoption all need solving at once.
How does a single integration project turn into a model that accelerates every one after it? Two use cases from pharmaceutical manufacturing.
What is an Industrial Data Fabric? Not a new system on top, but the layer underneath — and what that delivers.
Available data is not usable data. Why the application layer decides whether a data project pays off – and who is allowed to build a view.
The data flows, the project is signed off – and production still uses Excel. Why this gap appears systematically, and where the project boundary sits.
What can the framework do that Inmation cannot? Why the question matters – and which question actually decides it in operations.
When does technology alone stop being enough for a data project in pharma? When systems, context, and adoption all need solving at once.
How does a single integration project turn into a model that accelerates every one after it? Two use cases from pharmaceutical manufacturing.
What is an Industrial Data Fabric? Not a new system on top, but the layer underneath — and what that delivers.
Why do MES and data projects in pharma fail? The patterns and the early indicators.
How can production data leave the validated plant without putting compliance at risk? GxP — a question of architecture.
Why doesn't more data lead to better decisions in pharma manufacturing? Because it sits in silos without shared context.
